Comparative Pharmacology
Head-to-head clinical analysis: DORAL versus LORAZEPAM INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORAL versus LORAZEPAM INTENSOL.
DORAL vs LORAZEPAM INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
15-30 mg orally at bedtime, maximum 60 mg/day.
0.5-2 mg orally every 6-8 hours as needed. Maximum 4 mg/day.
None Documented
None Documented
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in elderly (15-20 hours) and patients with hepatic impairment (up to 30-40 hours).
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Renal excretion of glucuronide conjugates; <1% unchanged drug excreted renally. Fecal elimination accounts for approximately 10% of administered dose.
Category C
Category D/X
Benzodiazepine
Benzodiazepine